Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
KROS-201
i
Other names:
KROS-201, activated T cells
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Kairos Pharma
Drug class:
T-cell stimulant
Related drugs:
‹
TC-210 (7)
BRG01 (1)
SAR443216 (1)
CDX 1127 (1)
23ME-00610 (0)
ABIO-0501 (0)
ADG138 (0)
ADXS-503 (0)
AGX-148 (0)
naptumomab estafenatox (0)
BPT-143 (0)
BS006 (0)
Bria-OTS (0)
CD30 biAb-AATC (0)
CDR101 (0)
CER-1236 (0)
GEN-001 (0)
GIM-122 (0)
GX301 (0)
HJ-N-001 (0)
GCC4002 (0)
JANX008 (0)
JNJ-8543 (0)
KSH01 (0)
MP0533 (0)
NEO_PLIN2101 (0)
NX-1607 (0)
darleukin/fibromun (0)
PM3023 (0)
RPTR-147:1 (0)
SCG101 (0)
TAC100-HER2 (0)
TC-510 (0)
TCRT-ESO-A2 (0)
tabelecleucel (0)
UMG2-CD3 BTCE (0)
CF33-hNIS (0)
IRX-2 (0)
mRNA-4359 (0)
pTTL (0)
TC-210 (7)
BRG01 (1)
SAR443216 (1)
CDX 1127 (1)
23ME-00610 (0)
ABIO-0501 (0)
ADG138 (0)
ADXS-503 (0)
AGX-148 (0)
naptumomab estafenatox (0)
BPT-143 (0)
BS006 (0)
Bria-OTS (0)
CD30 biAb-AATC (0)
CDR101 (0)
CER-1236 (0)
GEN-001 (0)
GIM-122 (0)
GX301 (0)
HJ-N-001 (0)
GCC4002 (0)
JANX008 (0)
JNJ-8543 (0)
KSH01 (0)
MP0533 (0)
NEO_PLIN2101 (0)
NX-1607 (0)
darleukin/fibromun (0)
PM3023 (0)
RPTR-147:1 (0)
SCG101 (0)
TAC100-HER2 (0)
TC-510 (0)
TCRT-ESO-A2 (0)
tabelecleucel (0)
UMG2-CD3 BTCE (0)
CF33-hNIS (0)
IRX-2 (0)
mRNA-4359 (0)
pTTL (0)
›
Associations
News
Trials
Filter by
Latest
5ms
Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma (clinicaltrials.gov)
P1, N=10, Not yet recruiting, Jeremy Rudnick, M.D | Trial completion date: Jun 2025 --> Dec 2026 | Trial primary completion date: Jun 2023 --> Dec 2025
5 months ago
Trial completion date • Trial primary completion date
|
KROS-201
over2years
Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma (clinicaltrials.gov)
P1, N=10, Not yet recruiting, Jeremy Rudnick, M.D
over 2 years ago
New P1 trial
|
HER-2 (Human epidermal growth factor receptor 2) • IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2)
|
CD133 expression • HLA-A2 positive
|
KROS-201
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login